• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sunesis Pharmaceuticals

edit

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

Recent Milestones

edit

• 
  Sunesis Pharmaceuticals — Sunesis Prices $15.5 Million Offering (10/1/10)
  Posted 10/3/10 at 9:40pm via sunesis.com
• 
  Sunesis Pharmaceuticals received $43.5M in Venture Round funding. (4/7/09)
  Posted 4/12/09 at 11:31am via pehub.com
• 
  Went public with stock symbol NASDAQ:SNSS.
  Posted 10/3/10 at 9:40pm
• 
  Sunesis Pharmaceuticals added Deniel Adelmam as Senior Vice President of Development and Chief Medical Officer.
  Posted 4/17/13 at 3:23am

Videos

Screenshots

edit

Stock Price

Sources

1. VCs PIPE $43.5 Million to Sunesis Pharma (pehub.com) [edit]
Sunesis Prices $15.5 Million Offering (ir.sunesis.com) [edit]